ASH News Daily 2017 - Issue 2 - C-1

ASH NEWS DAILY
®

59th Annual Meeting of the American Society of Hematology
Issue 2, Section C
Sunday, December 10, 2017
Atlanta, GA
Read this issue online at

www.hematology.org/ashnewsdaily2017_sunday
Follow us on Twitter using #ASH17

ATTENDEE
SERVICES
ASH Central
Located in Building B, Level 1, Hall B1 of the
Georgia World Congress Center, ASH Central
is a place where meeting attendees can
gather to collaborate, relax, view sessions
remotely, or purchase ASH products. Offered
at ASH Central:
* ASH Live: Remote Session Viewing
* Collaboration Rooms
* ASH Store
* Selfie Zone
* ASH Foundation Donor Lounge
* ASH Trainee Lounge
* ASH News TV
* Hematology MeetUps
ASH Store
ASH has a variety of offerings to aid hematologists in their professional development.
Peruse the latest ASH educational products
and services, including:
* American Society of Hematology SelfAssessment Program (ASH®SAP),
Sixth Edition
* How I Treat Compendium: A Compendium for the Practicing Hematologist
* Hematology 2017, ASH Education
Program
* 2017 ASH Annual Meeting Webcast
Hematology MeetUps
Multiple seating areas with tables and chairs
will be placed in the lobby areas of the center to enable attendees to meet one another
for informal, impromptu conversations and
small meetings. Look for MeetUp areas
designated by the red stars on the convention center maps in this section.
Wheelchair-accessible ASH Shuttles
ASH has partnered with Kushner & Associates for wheelchair-accessible ASH shuttles
from hotels on the shuttle route. Please see
the ASH shuttle supervisor at the Georgia
World Congress Center during shuttle hours.
Restaurant Reservation Desk
Located in Building A, Level 4 of the International Boulevard Concourse at the Georgia
World Congress Center, the Restaurant Reservations Desk offers complimentary restaurant
reservation services and features brochures
on attractions in the metro Atlanta area.

IN THIS SECTION
Meeting on Hematologic
Malignancies
C-3
Exhibit Hall Map
C-6
Convention Center,
Hotel Maps
C-10

ASH Announces Election of Three
to Executive Committee

A

SH recently announced
the election of three new
members to its Executive Committee, the governing
body of the organization, for
terms beginning after the annual meeting. Stephanie Lee,
MD, will serve a one-year term
as vice president followed by
successive terms as presidentelect and president. Agnes Lee,
MD, and Joseph Mikhael, MD,
will each serve four-year terms
as councillors.
"In this time of unprecedented scientific progress, ASH continues to play a leading role in
ensuring that these research
advances are translated to the
bedside to improve the care of
hematology patients," said 2017
ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics
and Jerome Lipper Myeloma
Center at Dana-Farber Cancer
Institute in Boston. "It is exciting

to have such a diverse and accomplished group of leaders helping
to guide the Society as we work
with policymakers, educators, researchers, clinicians, patients, and
other stakeholders to shape the
future of hematology and work
toward our goal of conquering
blood diseases worldwide."
Dr. Stephanie Lee is a member
of the Fred Hutchinson Cancer
Research Center and a professor
at the University of Washington
in Seattle. Her research interests
include outcomes and health
services research in hematologic
malignancies and allogeneic hematopoietic cell transplantation,
and late effects of hematopoietic
cell transplantation, particularly
chronic graft-versus-host disease.
She has been a member of ASH
for 22 years, and during that time
has served in various leadership
roles representing the Society,
most recently serving as ASH secretary. She previously chaired the

Scholar Awards Program Study
Section and has participated in
many educational and career
development programs. As vice
president of ASH, Dr. Lee aims
to grow ASH's programs and
activities by investing where
ASH can make a difference. She
will work to increase public appreciation and understanding of
hematology research and plans
to share her rewarding experience at ASH by motivating other members to be more involved
in ASH's activities.
Dr. Agnes Lee is a professor
of medicine at the University of
British Columbia (UBC), director of the Thrombosis Program
at Vancouver Coastal Health
and UBC, and director of the
Hematology Research Program
at Vancouver General Hospital.
Her research interests include
cancer-associated thrombosis,
»» ELECTION Page C-26

Research Agenda Updates Mark Emerging
Priorities and Discoveries

T

The ASH Agenda for Hematology Research, is a "living"
Society publication that is updated regularly to reflect current and
emerging areas of research priorities.
It serves as a roadmap for the prioritization of research support across
the entire field of hematology and
includes recommendations for dedicated resources from funding agencies and foundations. The process for
updating the agenda is coordinated
by the ASH Committee on Scientific
Affairs and the 18 Scientific Committees and includes input from the
hematology community through
an open comment period. One such
comment period was recently held,
resulting in several updates to the
agenda, highlighted below.
The genomic profiling and chemical biology section of the agenda has

The ASH Agenda for Hematology Research may be considered a reference to the entire hematology community -
one that can be used as a resource for publications, grant
applications, and other efforts. On the whole, the agenda
represents some of the most promising strategies to help
hematologists overcome the limitations of current
therapies and accelerate momentum to find cures.

been re-named to "precision medicine," and will now prioritize 1) specific areas of fundamental research
such as genomics and epigenetics
that can foster better understanding
of patient predisposition to disease
and response to therapy; 2) facilitating the integration of genomic and
epigenomic profiling into drug discovery efforts via predictive preclinical models; and 3) renewed emphasis on a secure infrastructure for

hosting, sharing, and facilitating genomic data interpretation for clinical
trial design and drug development.
In the area of venous thromboembolic disease (VTE), research
priorities are now directed toward
1) evaluating the role of current antithrombotic agents in preventing
venous thromboembolism in highrisk populations; 2) identifying new
»» RESEARCH Page C-20
http://www.hematology.org/ashnewsdaily2017_sunday
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2
